Stock Quote Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Markets Stocks ETFs Tools Overview News Currencies International Treasuries Protagonist Therapeutics Inc (NQ: PTGX ) 8.200 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jul 6, 2022 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 8.200 Bid (Size) 7.670 (2) Ask (Size) 9.370 (2) Prev. Close 8.200 Today's Range 8.200 - 8.200 52wk Range 6.910 - 50.54 Shares Outstanding 48,413,555 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year Top News More News 12 Health Care Stocks Moving In Tuesday's After-Market Session July 05, 2022 Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) stock rose 14.5% to $0.53 during Tuesday's after-market session. The company's market cap stands at $14.0 million. Via Benzinga Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shareholder Alert: Investigation over Possible Wrongdoing June 27, 2022 San Diego, CA -- (SBWIRE) -- 06/27/2022 -- Certain directors of Protagonist Therapeutics, Inc. are under investigation over potential breaches of fiduciary duties. Via SBWire Performance YTD -76.78% -76.78% 1 Month -7.66% -7.66% 3 Month -66.53% -66.53% 6 Month -76.30% -76.30% 1 Year -81.83% -81.83% More News Read More 3 Biotech Stocks to Buy Before They Boom June 01, 2022 Via InvestorPlace The Daily Biotech Pulse: INmune Bio's Planned Alzheimer's Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures May 24, 2022 Via Benzinga Stocks That Hit 52-Week Lows On Tuesday April 26, 2022 Via Benzinga Why Protagonist Therapeutics Shares Are Crashing Today April 26, 2022 Via Benzinga The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More May 22, 2022 Via Benzinga 7 Micro-Cap Stocks to Buy and Hold for the Next 10 Years May 11, 2022 Via InvestorPlace Investigation Reminder: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the Firm April 29, 2022 Via NewMediaWire Topics Regulatory Compliance Exposures Legal Product Safety Regulatory Investigation Alert: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the Firm April 29, 2022 Via NewMediaWire Topics Regulatory Compliance Exposures Legal Product Safety Regulatory 71 Biggest Movers From Yesterday April 27, 2022 Via Benzinga Mid-Afternoon Market Update: Crude Oil Rises Over 3%; Protagonist Therapeutics Shares Plummet April 26, 2022 Via Benzinga 12 Health Care Stocks Moving In Tuesday's Intraday Session April 26, 2022 Via Benzinga Stocks Flounder As Wall Street Rotates Out Of Tech April 26, 2022 Via Talk Markets Mid-Day Market Update: Nasdaq Down 400 Points; Arch Resources Shares Jump April 26, 2022 Via Benzinga 34 Stocks Moving In Tuesday's Mid-Day Session April 26, 2022 Via Benzinga The Daily Biotech Pulse - Tuesday, April,26 April 26, 2022 Via Talk Markets Futures Slide Ahead Of Tech Earnings Deluge April 26, 2022 Via Talk Markets Mid-Morning Market Update: Markets Open Lower; Dow Dips 300 Points April 26, 2022 Via Benzinga The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy April 26, 2022 Via Benzinga 12 Health Care Stocks Moving In Tuesday's Pre-Market Session April 26, 2022 Via Benzinga 18 Stocks Moving in Tuesday's Pre-Market Session April 26, 2022 Via Benzinga Protagonist Therapeutics Topline Data from Phase 2 IDEAL Study of PN-943 (450 mg BID) Miss Primary Endpoint April 25, 2022 Via Benzinga INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the Firm April 21, 2022 From The Schall Law Firm Via Business Wire INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. With Losses of $100,000 to Contact the Firm April 20, 2022 From The Schall Law Firm Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
